No new data released — this is a timeline update. The key catalyst remains the interim Phase 2b data readout in 4Q 2026. Monitor for any data disclosures or regulatory interactions before that date.
Price Chart
Executive Summary
Protara Therapeutics completed enrollment of the Phase 2b dose confirmation cohort (24 patients) in the THRIVE-3 registrational trial of IV Choline Chloride for intestinal failure patients dependent on parenteral support. The company remains on track to report interim results in 4Q 2026. This is a routine operational milestone with no new data released, and the stock's historical reaction to similar updates has been negative.
Key Facts
- Completed enrollment of Phase 2b dose confirmation phase of THRIVE-3 trial evaluating IV Choline Chloride in 24 patients with intestinal failure dependent on parenteral support
- Interim results from the Phase 2b dosing cohort expected in 4Q 2026
- IV Choline Chloride has Orphan Drug and Fast Track designations from FDA
- THRIVE-3 is a registrational seamless Phase 2b/3 trial; Phase 3 will be randomized, double-blind, placebo-controlled with ~100 patients
- Primary endpoint: change in plasma choline concentration from baseline to week 8
Financial Impact
No financial data provided; clinical-stage company with no approved products or revenue
Risk Factors
- No clinical efficacy or safety data disclosed in this update
- IV Choline Chloride is still investigational; FDA approval is not guaranteed
- Company is pre-revenue with no approved products; dependent on financing
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3381589 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | Press Release | $2.40 | awaiting T+60 | — | $2.47 (+2.92%) |
Aug 11, 2026 11w ago | 8-K | $3.91 | awaiting T+60 | — | $2.47 (−36.83%) |
Aug 11, 2026 11w ago | Press Release | $3.91 | awaiting T+60 | — | $2.47 (−36.83%) |
Jun 29, 2026 17w ago | 8-K | $3.82 $3.54 | ▼ −7.33% | ▼ −10.15% | $2.47 (−35.34%) |
May 26, 2026 22w ago | EFFECT | $4.80 $3.96 | ▲ +17.50% | ▲ +20.22% | $2.47 (+48.54%) |
May 15, 2026 23w ago | Press Release | $5.10 $3.91 | ▼ −23.33% | ▼ −27.85% | $2.47 (−51.57%) |
May 13, 2026 23w ago | 8-K | $5.20 $4.12 | ▼ −20.77% | ▼ −25.21% | $2.47 (−52.50%) |
May 13, 2026 23w ago | Press Release | $5.20 $4.12 | ▼ −20.77% | ▼ −25.21% | $2.47 (−52.50%) |
Apr 28, 2026 26w ago | DEFA14A | $5.17 $4.02 | ▼ −22.24% | ▼ −26.35% | $2.47 (−52.22%) |
Mar 10, 2026 33w ago | Press Release | $5.71 $4.22 | ▼ −26.09% | ▼ −37.50% | $2.47 (−56.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers